Assembly Biosciences, Inc.

ASMB Healthcare Biotechnology

Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024. In the quarter to June 2026, revenue grew 38.9%, EPS grew 85.0% and free cash flow grew 7.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

20.34 2.43 −10.67%
Market cap
$463.6M
P/E
19.9×
Fwd P/E
−21.1×
Dividend yield
—
F-score
4/9
Altman Z
1.06
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 26.94
P/S ratio
8.73 5.27 6.60 6.92
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(21.46) 26.78 (21.22) (33.45)
P/B ratio
1.78 1.84 2.36 1.70
Price to Tangible BV
2.30 2.31 2.99 1.96
EV/Sales
2.48 1.84 3.41 2.64
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(1.65) (3.24) (6.10) (5.14)
EV/FCF
(1.65) (3.24) (6.08) (5.13)
Quick Ratio
4.37 5.11 6.49 13.70
Current Ratio
4.44 5.22 6.65 13.99
Net Debt/EBITDA
20.25 (13.06) 18.68 45.17
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.22 0.38 0.43 0.36
Operating CF/Net income
1.65 0.64 2.43 4.02
Capex/Depreciation
0.07 0.03 0.02 0.00
Interest Coverage
— — — 2.55
Research and Development Expense of Revenue
153.74% 40.62% 181.42% 111.54%
Selling, General and Administrative Expense of Revenue
47.13% 12.76% 57.02% 35.90%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
15.48% 3.44% 13.59% 18.06%
Graham Net Nets
0.55 0.53 0.42 0.58
Graham Number
0.00 0.00 0.00 19.29
Earnings Yield
(18.71%) (2.18%) (0.40%) 3.71%
Free Cash Flow Yield
(17.18%) (10.79%) (8.49%) (7.44%)
Revenue per Share
0.85 3.79 0.49 0.71
Operating CF per Share
(1.19) 1.27 (1.31) (0.82)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(1.20) 1.27 (1.31) (0.82)
Cash per Share
18.33 22.13 13.41 16.99
Shareholders Equity per Share
14.40 18.44 11.75 16.21
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
14.40 18.44 11.75 16.21
Free Cash Flow
(15.17) 14.21 (22.12) (15.49)
Working Capital
183.43 205.77 197.62 304.53
Capital Expenditures
(0.04) (0.02) (0.02) 0.00
Net Current Asset Value
179.51 203.71 195.72 302.80
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
0.63 0.54 0.25 0.43
Average Payables
1.51 0.88 1.00 0.96
Average Assets
170.13 188.38 167.26 205.81
Average Common Equity
104.35 120.06 112.87 161.87

Fold the line items

Columns are period end dates